



PB 5 of 2025

National Health (Highly Specialised Drugs Program) Special Arrangement Amendment (February Update) Instrument 2025

National Health Act 1953

I, REBECCA RICHARDSON, Assistant Secretary, Pricing and PBS Policy Branch, Technology Assessment and Access Division, Department of Health and Aged Care, delegate of the Minister for Health and Aged Care, make this Instrument under subsection 100(2) of the *National Health Act 1953*.

Dated 30th January 2025

REBECCA RICHARDSON
Assistant Secretary
Pricing and PBS Policy Branch
Technology Assessment and Access Division

Contents

1	Name.....	1
2	Commencement.....	1
3	Authority	1
4	Schedules.....	1
Schedule 1—Amendments		2
	<i>National Health (Highly Specialised Drugs Program) Special Arrangement 2021 (PB 27 of 2021)</i>	2

1 Name

- (1) This instrument is the *National Health (Highly Specialised Drugs Program) Special Arrangement Amendment (February Update) Instrument 2025*.
- (2) This instrument may also be cited as PB 5 of 2025.

2 Commencement

- (1) Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.

Commencement information		
Column 1	Column 2	Column 3
Provisions	Commencement	Date/Details
1. <i>The whole of this instrument</i>	<i>1 February 2025</i>	<i>1 February 2025</i>

Note: This table relates only to the provisions of this instrument as originally made. It will not be amended to deal with any later amendments of this instrument.

- (2) Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.

3 Authority

This instrument is made under subsection 100(2) of the *National Health Act 1953*.

4 Schedules

Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.

Schedule 1—Amendments

National Health (Highly Specialised Drugs Program) Special Arrangement 2021 (PB 27 of 2021)

[1] Schedule 1, entry for Adalimumab in the form Injection 40 mg in 0.4 mL pre-filled syringe

omit:

Adalicip	C12120 C14061 C14063 C14064 C14107 C14136	See Schedule 2	See Schedule 2
----------	---	----------------	----------------

[2] Schedule 1, entry for Maraviroc in each of the forms: Tablet 150 mg; and Tablet 300 mg

insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

Maraviroc Waymade	C5008	120	5
-------------------	-------	-----	---

[3] Schedule 1, entry for Tenofovir in the form Tablet containing tenofovir disoproxil maleate 300 mg

(a) *omit:*

Tenofovir Disoproxil Mylan	C6980 C6982 C6983 C6984 C6992 C6998 C10362	P10362	60	2
-------------------------------	---	--------	----	---

(b) *omit:*

Tenofovir Disoproxil Mylan	C6980 C6982 C6983 C6984 C6992 C6998 C10362	P6980 P6982 P6983 P6984 P6992 P6998	60	5
-------------------------------	---	---	----	---